This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with chemotherapy — Abraxane (nab-paclitaxel) plus carboplatin — as a first-line treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors do not have any mutations in the EGFR or ALK genes. Tecentriq is…
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that Kadcyla (ado-trastuzumab emtansine) be approved as an adjuvant (post-surgery) treatment for certain HER2-positive early breast cancers, the treatment’s maker, Genentech, has announced. Specifically, the advisory committee for the European Union’s…
This post was originally published on this site “All that is gold does not glitter / Not all those who wander are lost / The old that is strong does not wither / Deep roots are not reached by the frost.” — J.R.R.Tolkien Why do people with Alzheimer’s disease wander? The tendency to wander in…
This post was originally published on this site Longer sequence repeats in or near two genes may be linked to a higher risk of late-onset Alzheimer’s disease, a study reports. The study “Alzheimer Disease Pathology-Associated Polymorphism in a Complex Variable Number of Tandem Repeat Region Within the MUC6 Gene, Near the AP2A2 Gene” was published…
This post was originally published on this site Treatment with Myovant Sciences’ relugolix induces a long-lasting reduction in testosterone to castrate levels — similar to testosterone levels after medical or chemical castration — in nearly all men with advanced prostate cancer who are sensitive to androgen deprivation therapy, updated results from the HERO Phase 3…
This post was originally published on this site STRO-002, an investigational antibody-drug conjugate being developed by Sutro Biopharma, is safe and shows promising efficacy in women with advanced ovarian, fallopian tube, or primary peritoneal cancer, early Phase 1 clinical data show. The findings were presented during the recent AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference…
This post was originally published on this site Early treatment with a triple combination therapy containing Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone in patients with high-risk smoldering multiple myeloma — a precursor of multiple myeloma — is safe and may halt the disease’s progression into the full-blown condition, a Phase 2 trial shows. The results will…
This post was originally published on this site A branch of the European Medicines Agency voiced support for Revlimid (lenalidomide) in combination with rituximab becoming a treatment option for adults with follicular lymphoma who responded poorly to, or whose disease returned after, prior therapy. The Committee for Medicinal Products for Human Use (CHMP), an advisory committee for the…
This post was originally published on this site High blood levels of two hormones — insulin-like growth factor-I (IGF-I) and free testosterone — are associated with increased risk of prostate cancer later in life, a new study suggests. The study, “Serum hormones and prostate cancer incidence and mortality in UK Biobank,” was presented at the recent 2019 National…
This post was originally published on this site The Italian Medicines Agency (AIFA) has approved Clovis Oncology’s Rubraca (rucaparib) for reimbursement in Italy as a maintenance therapy for women with relapsed ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA status. This follows Rubraca’s approval for that indication by the European Commission early this year.…
